Trials / Conditions / EGF-R Positive Non-Small Cell Lung Cancer

EGF-R Positive Non-Small Cell Lung Cancer

21 registered clinical trials studyying EGF-R Positive Non-Small Cell Lung Cancer — 7 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLC NCT06557096	Second Affiliated Hospital of Nanchang University	EARLY_Phase 1
Not Yet Recruiting	The Feasibility of Dynamic Liquid Biopsy Monitoring During Neoadjuvant Treatment for EGFR-mutated NSCLC NCT06287593	Zhejiang University	N/A
Recruiting	The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC NCT06109558	Hunan Province Tumor Hospital	Phase 1 / Phase 2
Not Yet Recruiting	Study to Evaluate SBRT for EGFR Mutant NSCLC Patients Receiving Osimertinib (CULTRO) NCT05998993	Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo	N/A
Unknown	Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer NCT05573373	Affiliated Hospital of Jiangnan University	Phase 1
Unknown	Endobronchial Ultrasound Needle Aspiration With and Without Suction NCT05110950	Università Politecnica delle Marche	N/A
Active Not Recruiting	Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With E NCT05256290	Black Diamond Therapeutics, Inc.	Phase 1 / Phase 2
Recruiting	An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain Metastasis NCT06352502	Tang-Du Hospital	—
Terminated	(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC NCT05153408	Blueprint Medicines Corporation	Phase 1
Not Yet Recruiting	Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Aden NCT05132985	Liaoning Cancer Hospital & Institute	Phase 2
Unknown	Adjuvant Targeted-therapy for Patients With Resected High-risk EGFR-mutant Stage IB-IIA Non-small Cell Lung Ca NCT05165355	Tongji University	Phase 2
Unknown	Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC NCT04989322	Dr Joanne CHIU	Phase 2
Terminated	(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC NCT04862780	Blueprint Medicines Corporation	Phase 1
Recruiting	A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continua NCT05033691	Hadassah Medical Organization	N/A
Withdrawn	Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advance NCT04464967	NKGen Biotech, Inc.	Phase 1 / Phase 2
Active Not Recruiting	Dacomitinib in Lung Cancer With Uncommon EGFR Mutations NCT04504071	Shanghai Chest Hospital	Phase 2
Unknown	Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer NCT03749213	Betta Pharmaceuticals Co., Ltd.	Phase 2
Unknown	Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung NCT03349203	Betta Pharmaceuticals Co., Ltd.	Phase 2
Completed	First Line Osimertinib in the Real World: an Inter-regional Prospective Study NCT04965701	Istituto Oncologico Veneto IRCCS	—
Unknown	Stereotactic Ablative Radiotherapy in Synchronous and Metachronous Oligo-Metastatic Non Small Cell Lung Cancer NCT06207292	Radiotherapy Oncology Centre "Santa Maria" Hospital	N/A
Completed	The Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR NCT04640870	Hellenic Cooperative Oncology Group	—